Payment overview · 2025
General Payments
$227.14
12 reported records · 7 companies
Healthcare provider profile · identity verified
Sanjay Serrao, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JASPER, GA · NPI 1346204062
Verified facts
What the public records show
CMS Open Payments records show Sanjay Serrao, MD received $227.14 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.37 | 23.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.34 | 16.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.01 | 15.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.02 | 14.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.84 | 10.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.64 | 10.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.92 | 10.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $227.14 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.37 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.34 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.02 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.59 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
148 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 996 | 273 |
| Levothyroxine Sodium | Levothyroxine Sodium | 990 | 241 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 697 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 683 | 183 |
| Losartan Potassium | Losartan Potassium | 624 | 175 |
| Lisinopril | Lisinopril | 621 | 179 |
| Omeprazole | Omeprazole | 490 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 400 | 101 |
| Montelukast Sodium | Montelukast Sodium | 399 | 116 |
| Metformin Hcl | Metformin Hcl | 390 | 119 |
| Tamsulosin Hcl | Tamsulosin Hcl | 365 | 101 |
| Hydrochlorothiazide | Hydrochlorothiazide | 356 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 328 | 98 |
| Simvastatin | Simvastatin | 326 | 91 |
| Citalopram Hbr | Citalopram Hydrobromide | 306 | 74 |
| Trazodone Hcl | Trazodone Hcl | 294 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 283 | 72 |
| Sertraline Hcl | Sertraline Hcl | 254 | 65 |
| Carvedilol | Carvedilol | 250 | 69 |
| Gabapentin | Gabapentin | 249 | 78 |
| Allopurinol | Allopurinol | 239 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 237 | 102 |
| Glimepiride | Glimepiride | 232 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 212 | 55 |
| Famotidine | Famotidine | 189 | 63 |
| Meloxicam | Meloxicam | 175 | 65 |
| Potassium Chloride | Potassium Chloride | 175 | 37 |
| Ezetimibe | Ezetimibe | 173 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 43 |
| Synthroid | Levothyroxine Sodium | 148 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 74 |
| Paroxetine Hcl | Paroxetine Hcl | 128 | 25 |
| Furosemide | Furosemide | 123 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 123 | 34 |
| Ozempic | Semaglutide | 123 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 118 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 26 |
| Alendronate Sodium | Alendronate Sodium | 104 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 32 |
| Buspirone Hcl | Buspirone Hcl | 97 | 18 |
| Alprazolam | Alprazolam | 96 | 19 |
| Spironolactone | Spironolactone | 94 | 20 |
| Methylprednisolone | Methylprednisolone | 93 | 83 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 21 |
| Tramadol Hcl | Tramadol Hcl | 90 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 32 |
| Atenolol | Atenolol | 82 | 22 |
| Metformin Hcl Er | Metformin Hcl | 82 | 24 |
| Bupropion Xl | Bupropion Hcl | 81 | 30 |
| Finasteride | Finasteride | 75 | 22 |
| Januvia | Sitagliptin Phosphate | 74 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 66 |
| Valacyclovir | Valacyclovir Hcl | 66 | 30 |
| Eliquis | Apixaban | 64 | 20 |
| Celecoxib | Celecoxib | 63 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | suppressed |
| Memantine Hcl | Memantine Hcl | 58 | 13 |
| Glipizide | Glipizide | 57 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 14 |
| Fenofibrate | Fenofibrate | 56 | 15 |
| Jardiance | Empagliflozin | 56 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 14 |
| Benazepril Hcl | Benazepril Hcl | 48 | 14 |
| Estradiol | Estradiol | 48 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 14 |
| Azelastine Hcl | Azelastine Hcl | 47 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 16 |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Nateglinide | Nateglinide | 45 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Verapamil Er | Verapamil Hcl | 44 | 12 |
| Lovastatin | Lovastatin | 41 | 12 |
| Bumetanide | Bumetanide | 40 | suppressed |
| Valsartan | Valsartan | 39 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 14 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | 11 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Testosterone | Testosterone | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 23 |
| Prednisone | Prednisone | 29 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 27 |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 22 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 22 | suppressed |
| Nystatin | Nystatin | 22 | 16 |
| Trulicity | Dulaglutide | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Zaleplon | Zaleplon | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 11 |
| Irbesartan | Irbesartan | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 13 |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 12 |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Belsomra | Suvorexant | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $227.14 · 12 records | Novo Nordisk Inc | Cologuard Collection Kit, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, Korlym, MOUNJARO, Ozempic, Rybelsus, UBRELVY, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error